<DOC>
	<DOCNO>NCT01940081</DOCNO>
	<brief_summary>Rationale : Sudden cardiac death , mainly cause ventricular arrhythmia ( VA ) , major cause morbidity mortality non-ischemic cardiomyopathy ( NICM ) . Therapies effectively prevent VA lacking . Improved understanding substrate mechanism VA NICM may allow effective , individualized substrate-based therapy develop . In addition , risk stratification NICM need improved therapy allocate efficiently . Objectives : 1 ) To improve understand underlie pro-arrhythmic substrate electrophysiologic mechanism VA NICM , develop individualized treatment VA base identified substrate . 2 ) To improve risk stratification VA sudden cardiac death NICM base substrate characteristic . 3 ) evaluate disease progression NICM . Hypothesis : Improved understanding substrate mechanism VA NICM may allow effective , individualized substrate-based therapy develop . Study design : A prospective cohort study . Study population : The study population consist three group ( A , B C ) : NICM patient document VA , suspect VA intermediate high risk VA ( accord establish criterion ) refer cardiac surgery ( group A ) , NICM patient document VA , suspect VA high risk VA refer cardiac surgery ( group B ) control group consist patient without NICM refer cardiac surgery ( group C ) . Evaluation : All patient evaluate accord current standard patient NICM . Evaluation include 24h-Holter , echocardiography , coronary angiogram contrast-enhanced MRI ( CE-MRI ) . If CE-MRI perform another hospital , additional recording perform hospital . Additionally , blood sample ( arterial , cardiac venous peripheral venous ) collagen turnover marker take patient . 123-iodine metaiodobenzylguanidine ( 123-I MIBG ) imaging , electrophysiologic study endomyocardial biopsy perform group A B. Intra-operative biopsy perform group B C. Intervention : In group B , intra-operative mapping cryo-ablation postoperative electrophysiologic study perform patient subepicardial late enhancement MRI induce VA suspect subepicardial origin . Main study parameters/endpoints : The main study parameter extent , location pattern fibrosis image biopsy specimen . The main study endpoint inducibility VA , type induce VA , spontaneous VA type spontaneous VA .</brief_summary>
	<brief_title>The Leiden Nonischemic Cardiomyopathy Study</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Inclusion criterion , group A : Nonischemic cardiomyopathy Documented ventricular arrhythmia , suspect ventricular arrhythmia ( e.g . outofhospital cardiac arrest , palpitation syncope ) high risk ventricular arrhythmia ( LVEF ≤ 35 % ) intermediate risk ventricular arrhythmia ( LVEF ≤ 50 % late enhancement contrastenhanced MRI ) Admission cardiac surgery Inclusion criterion , group B : Nonischemic cardiomyopathy Documented ventricular arrhythmia suspect ventricular arrhythmia ( e.g . outofhospital cardiac arrest , palpitation syncope ) high risk ventricular arrhythmia ( LVEF ≤ 35 % ) Admission cardiac surgery ( e.g. , mitral valve annuloplasty CorCap ) Inclusion criterion , group C : Patients undergo aortic valve replacement coronary artery bypass graft surgery Exclusion criterion , group : Age &lt; 18 year &gt; 80 year Inadequate patient competence Pregnancy Inability comply protocol due haemodynamic instability Exclusion Criteria , group A B : Other cardiomyopathy ( e.g. , prior myocardial infarction , infiltrative cardiac disease sarcoidosis , amyloidosis Chagas cardiomyopathy , arrhythmogenic right ventricular cardiomyopathy/dysplasia , hypertrophic cardiomyopathy , noncompaction cardiomyopathy congenital heart disease ) Exclusion criterion , group C : Nonischemic cardiomyopathy Prior myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cardiomyopathy , Dilated</keyword>
	<keyword>Tachycardia , Ventricular</keyword>
	<keyword>Ventricular Fibrillation</keyword>
	<keyword>Arrhythmias , Cardiac/etiology</keyword>
	<keyword>Arrhythmias , Cardiac/physiopathology</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>3-Iodobenzylguanidine/diagnostic use</keyword>
	<keyword>Sympathetic Nervous System/radionuclide image</keyword>
	<keyword>Electrophysiologic Techniques , Cardiac</keyword>
	<keyword>Biopsy</keyword>
	<keyword>Genetic Testing</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Electrocardiography , Ambulatory</keyword>
	<keyword>Exercise Test</keyword>
</DOC>